Daewoong Group affiliate CGBio and its subsidiary CGBio Medtech presented a spinal treatment strategy that combines robotic navigation, endoscopic surgery, and bone regeneration therapy at a global spine congress.

Bioregenerative medicine specialist CGBio and CGBio Medtech announced that they participated in the Global Spine Congress “GSC 2026 (Global Spine Congress 2026),” held in Istanbul, Türkiye, from May 27 to 30, and introduced to global medical professionals a spinal treatment strategy that combines robot navigation–based minimally invasive spine surgery with rhBMP-2–based bone regeneration therapy.

GSC is an international spine congress organized by AO Spine. It is regarded as an academic event where spine surgeons, researchers, and medical professionals from around the world share the latest surgical techniques and clinical research findings.

CGBio and CGBio Medtech showcased a portfolio spanning from spinal surgery to bone fusion and bone regeneration therapy at this year’s congress. Centered on the spinal surgery robot navigation system “CUVIS-Spine,” they presented a treatment strategy linking endoscopic spine surgery equipment, spinal implants, and rhBMP-2–based bone fusion solutions.

At the exhibition booth, the companies introduced key product lines in the spinal and bone regeneration fields, including CGBio’s EXCENDER, NOVOMAX Fusion, NOVOSIS, and CUVIS-Spine, as well as CGBio Medtech’s INNOVERSE Screw.

The portfolio that combines CGBio Medtech’s internalized minimally invasive spine surgery solutions with CGBio’s bone fusion and regenerative medicine technologies was presented as a spinal treatment strategy that enhances surgical accuracy and reduces the recovery burden on patients.

The congress also featured an endoscopy workshop and clinical sessions, which were hands-on training programs for global medical professionals. Professor Yong-San Ko of Kyungpook National University Hospital participated as a hands-on training instructor and introduced minimally invasive spine surgery techniques, including robot-assisted endoscopic decompression using CUVIS-Spine and unilateral biportal endoscopic lumbar interbody fusion (UBE-LIF).

The surgical technique and clinical presentation sessions were conducted under the chairmanship of Professor Jeffrey C. Wang of the Keck School of Medicine at the University of Southern California and Professor Sangwook Tim Yoon of Emory University. According to CGBio, the sessions included presentations on the latest bone fusion strategies in spinal fusion surgery and the clinical efficacy of rhBMP-2–based bone regeneration therapy.

Professor Jin-Sung Kim of Seoul St. Mary’s Hospital presented long-term follow-up clinical results for NOVOMAX Fusion. Professor Sang-Min Park of Seoul National University Bundang Hospital presented large-scale follow-up data on NOVOSIS, an rhBMP-2–based bone substitute used in transforaminal lumbar interbody fusion (TLIF). Based on these data, Professor Park shared clinical experience confirming bone fusion outcomes and safety compared with autologous bone.

Professor Naresh Kumar of the National University Hospital in Singapore presented a comparative study on rhBMP-2 carrier formulations, explaining the impact of carriers on treatment outcomes in bone fusion therapy and their clinical significance.

CGBio plans to use this congress as a springboard to expand its overseas business for spinal implants and regenerative medicine products, focusing on Europe, the Middle East, Russia, and the CIS region. During the event, the company held meetings with major global corporations and distributors to discuss overseas market entry prospects for its spine and bone regeneration product lines.

CGBio also pursued a business agreement with a Hungarian distributor specializing in spinal implants to expand supply of its injectable artificial bone product Excelos Inject. Excelos Inject is an injectable artificial bone product based on biodegradable hydrogel and β-TCP.

With Vietnamese medical device company Nam Thanh, CGBio signed a strategic partnership agreement for its spinal implant product line. The two companies plan to target the southern Vietnam market, focusing on the LUMFIX spinal screw system, specialized for scoliosis surgery, and the expandable cage EXCENDER. They are also discussing an exclusive distribution contract with a value of up to USD 3.2 million.

In the global spinal treatment market, interest is growing in minimally invasive spine surgery, which improves surgical accuracy and reduces the recovery burden on patients. As treatment approaches that combine robot navigation technology, endoscopic surgery, and bone regeneration therapy gain attention, the importance of educational programs that share real surgical experience and clinical data is also rising.

Yoo Hyun-seung, CEO of CGBio, stated, “CGBio is building an integrated portfolio encompassing spinal implants, minimally invasive surgery solutions, and rhBMP-2–based bone regeneration therapy,” adding, “Through this GSC 2026, we were able to share clinical experience with global medical professionals while further strengthening the foundation for expanding into the European, Middle Eastern, and Asian markets.”

He continued, “Going forward, by offering solutions that combine robot navigation–based spinal surgery with regenerative medicine technology, we will continue to enhance clinical value and brand trust in the global spinal treatment market.”

Popular News